Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
155.01
+0.14 (+0.09%)
Streaming Delayed Price
Updated: 1:13 PM EDT, Mar 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
959,289
Open
155.64
Bid (Size)
154.98 (100)
Ask (Size)
155.05 (400)
Prev. Close
154.87
Today's Range
154.38 - 155.79
52wk Range
97.72 - 170.46
Shares Outstanding
N/A
Dividend Yield
2.58%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients
↗
March 16, 2026
FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.
Via
Benzinga
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income
↗
March 13, 2026
Via
Chartmill
Performance
YTD
+11.9%
+11.9%
1 Month
-6.7%
-6.7%
3 Month
+14.7%
+14.7%
6 Month
+25.7%
+25.7%
1 Year
+38.1%
+38.1%
More News
Read More
VYMI: This International ETF Could Help You Earn Higher Dividends
↗
March 12, 2026
Via
The Motley Fool
Topics
ETFs
3 ETFs to Avoid as Oil Shock Hits Markets
↗
March 12, 2026
Via
MarketBeat
Topics
ETFs
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals
↗
February 19, 2026
Via
Chartmill
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
March 10, 2026
Via
MarketMinute
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
March 10, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Lawsuit
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
↗
March 03, 2026
Via
The Motley Fool
Topics
Intellectual Property
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
↗
March 02, 2026
Via
MarketBeat
Topics
ETFs
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement
↗
February 28, 2026
Via
Benzinga
Topics
Lawsuit
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
February 26, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
↗
February 25, 2026
Via
The Motley Fool
Topics
Stocks
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
Via
MarketMinute
Topics
Intellectual Property
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
↗
February 24, 2026
Via
The Motley Fool
Topics
Intellectual Property
Retirement
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
Via
The Motley Fool
Topics
Earnings
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
↗
February 23, 2026
Via
The Motley Fool
Topics
Stocks
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
↗
February 22, 2026
Via
The Motley Fool
Topics
Intellectual Property
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
February 19, 2026
Via
MarketMinute
A Look Into Novartis Inc's Price Over Earnings
↗
February 17, 2026
Via
Benzinga
Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too?
↗
February 16, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts
↗
February 16, 2026
Via
The Motley Fool
Topics
ETFs
Stocks
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise
↗
February 13, 2026
Via
Benzinga
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
February 12, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
February 11, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via
MarketMinute
Topics
Intellectual Property
Frequently Asked Questions
Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 155.01
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 03/17/26 01:13 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.